AVI BioPharma Presents Updated Safety Data From Ongoing Systemic Trial Of AVI-4658 At 7th Annual Action Duchenne International Conference

AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, presented an update on preliminary safety data from its ongoing systemic Phase 1b/2 clinical trial of exon skipping AVI-4658 in patients with Duchenne muscular dystrophy (DMD) at the 7th Annual Action Duchenne Conference in London, UK...
This entry was posted in News from Other Sources. Bookmark the permalink. Both comments and trackbacks are currently closed.